A phase I dose escalation study of FLX925 (AMG 925), the first dual FLT3 and CDK4/6 inhibitor [90,91,92] in adults with relapsed or treatment refractory AML, demonstrated modest single-agent activity with a dose-limiting toxicity of increased creatinine (ClinicalTrials.govidentifier: NCT02335814). The gene discussed is CDK4; the disease is acute myeloid leukemia.